Convergence of biomarkers and risk factor trait loci of coronary artery disease at 3p21.31 and HLA region

Majid Nikpay1,2✉ and Ruth McPherson1,2✉

Here we seek to identify molecular biomarkers that mediate the effect of risk factors on coronary artery disease (CAD). We perform a SNP-based multiomics data analysis to find biomarkers (probes) causally associated with the risk of CAD within known genomic loci for its risk factors. We identify 78 biomarkers, the majority (64%) of which are methylation probes. We detect the convergence of several CNS and lifestyle trait loci and their biomarkers at the 3p21.31 and human leukocyte antigen (HLA) regions. The 3p21.31 locus was the most populated region in the convergence of biomarkers and risk factors. In this region, we noted as the BS gene becomes methylated the level of stomatin (STOM) in blood increases and this contributes to higher risk of CAD. In the HLA locus, we identify several methylation biomarkers associated with various CAD risk factors. SNPs in the CFB gene display a trans-regulatory impact on the GRIA4 protein level. A methylation site upstream of the APOE gene is associated with a higher protein level of S100A13 which in turn leads to higher LDL-C and greater CAD risk. We find UHRF1BP1 and ILRUN mediate the effect of obesity on CAD whereas methylation sites within NOS3 and CKIM mediate the effect of their associated-risk factors on CAD. This study provides further insight into the biology of CAD and identifies a list of biomarkers that mediate the impact of risk factors on CAD. A SNP-based initiative can unite data from various fields of omics into a single network of knowledge.

npj Genomic Medicine (2021) 6:12 ; https://doi.org/10.1038/s41525-021-00174-z

INTRODUCTION

GWAS studies have identified numerous loci associated with various complex phenotypes including the susceptibility to coronary artery disease (CAD). Multimomic approaches to the analysis of GWAS data provide a new means to understand the biology of these traits. Namely, we have GWAS data that catalog the associations between genome and the phenotype but cannot provide molecular insight and we also have GWAS data from omics studies that report associations between genome and various molecular features. By combining these two different sets of data, it is possible to identify genomic regions where SNP-association signals are consistent (co- localize) for a trait and a molecular feature (biomarker), then Mendelian randomization (MR) can be used to test whether change in the level of the biomarker is causally contributing to the trait (Fig. 1 and Supplementary Fig. 1). A similar design can relate and combine different sets of omics data to understand the whole organism at molecular and cellular levels.

We have used GWAS data to investigate the genetic architecture of CAD and reported it largely derives from the cumulative effect of common SNPs throughout the genome each of small effect size1-12. We also reported that CAD is the outcome of several phenotypically distinct but genetically inter-related risk factors5. We devised a SNP-based analysis plan based on the above paradigm to identify biomarkers contributing to the risk of CAD4,5. In this study, we have extended these studies to identify genomic loci through which CAD risk factors exert their effects.

RESULTS

Overview

Using our SNP-based multiomics data analysis plan (Fig. 1), we identified 78 biomarkers associated with various risk factors for CAD at GWAS significance level (P < 5e−8) as well as to CAD per se after correction for multiple testing (Supplementary Data 3). Although the mQTL datasets had the smallest sample sizes (Supplementary Data 1), majority of the identified biomarkers were methylation probes (68%). Transcription and protein probes accounted for 26% and 6% of the biomarkers, respectively. Summary association statistics for SNPs that we used to carry out these tests are available in Supplementary Data 4 and Supplementary Data 5.

We then obtained data from additional omic studies that also made their GWAS data publicly available and used this information to examine our results. The list of biomarkers that showed significant association (P < 0.05) following MR analysis is available in Supplementary Data 6. Of note, a lack of replication for a biomarker does not indicate a negative result. This is mainly because we used highly stringent statistical criteria to do the MR analysis. Namely, SNPs that (a) are in linkage equilibrium with each other (r² < 0.05); (b) associated with the biomarker at P < 5e−8; and (c) are not showing pleiotropic effect (HEIDI P < 0.01). Therefore, for number of biomarkers, we did not obtain enough SNPs to do the MR analysis. For example, we did not replicate the association of SELE protein level with CAD using data from Suhre et al.6. However, after relaxing our LD threshold to r² < 0.2, we found a higher level of SELE is causally contributing to lower risk of CAD [B = −0.05, P = 5e−13, Number of SNPs (N_{SNPs}) = 6] using pQTLs from this study.

Our analysis plan can provide insight at both molecular (Biomarker → Biomarker) and clinical levels (Biomarker → Trait); therefore, findings from these studies can be used to investigate our results as well. For example, we find that SNPs near SORT1 on chromosome 1 displays trans-regulatory impact on GRN on chromosome 17 (Supplementary Data 3) and this affects circulating levels of HDL. This finding is not unprecedented. SORT1 is an

1Ruddy Canadian Cardiovascular Genetics Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada. 2Atherogenomics Laboratory, University of Ottawa Heart Institute, Ottawa, ON, Canada. ✉email: mnikpay@ottawaheart.ca; rmcpherson@ottawaheart.ca

Published in partnership with CEGMR, King Abdulaziz University
extracellular receptor for GRN\(^7\). In addition, it is known that GRN contributes to the anti-inflammatory effect of HDL by forming a complex with HDL/apolipoprotein A-I\(^8\).

Among our identified biomarkers, seventeen were associated with CAD at GWAS significance (Supplementary Fig. 2A). We also noted the presence of several trans-regulatory effects (Supplementary Fig. 2B). Studying these trans-regulatory effects is important because they can provide novel insights into the molecular pathway whereby a biomarker exerts its effect. Below we review the most notable findings:

**LDL and S100A13**

We found the plasma protein level of S100A13 (S100 calcium-binding protein \(^13\)) is causally associated with higher LDL (\(\beta = 0.25, P = 4.75 \times 10^{-5}\)) and higher risk for CAD (\(\beta = 0.05, P = 9.78e^{-12}\)) (Supplementary Data 3). The interpretation of \(\beta\) estimate from the MR analysis can be explained in standard deviation (SD) units. Therefore, a \(\beta = 0.05\) (OR = 1.05) indicates that individuals whose S100A13 plasma protein levels are 1 SD above the population mean will have 1.05 times increase in risk to CAD.

We noted that the S100A13 protein level in the blood is under the trans-regulatory impact of SNPs at the APOE locus. Further analysis revealed, both APOE and S100A13 levels are under the regulatory impact of a methylation site (cg13375295) upstream of the APOE gene (Fig. 2). Higher methylation at this site was associated with lower levels of APOE (\(\beta = -3.7, P = 9.7e^{-10}\)) and S100A13 (\(\beta = -4.0, P = 1.4e^{-11}\)) in the blood. Previous studies also reported the trans-regulatory effect of APOE on S100A13\(^3,10\). MR analysis revealed that this gene has a causal impact on other cardiometabolic risk factors of CAD. We found that a higher level of S100A13 in the blood is associated (\(P < 5e^{-5}\)) with higher levels of TC, immature reticulocyte fraction, and a higher risk of T2D (Supplementary Fig. 2 and Supplementary Data 7). The protein encoded by this gene is a member of the S100 family of proteins. It exhibits calcium and lipid-binding properties and is highly expressed in the heart. In smooth muscle cells, S100A13 co-expresses with other family members in the nucleus and in stress fibers, suggesting diverse functions in signal transduction.

**Thrombosis and F8**

SNPs in the ABO locus are reported to have a trans-regulatory effect on protein levels of F8 (coagulation Factor VIII) in the blood. Factor VIII participates in the intrinsic pathway of blood coagulation; it is a cofactor for factor IXa which, in the presence of Ca\(^{2+}\) and phospholipids, converts factor X to the activated form Xa.

Here, we confirmed this effect (Supplementary Data 3) and noted that it is attributed to methylation sites within the ABO locus (Supplementary Data 8). We found multiple methylation sites within the ABO locus that show causal association with F8 protein levels. As displayed in Fig. 2, as ABO becomes methylated the level of F8 in the blood raises and this consequently increases the risk of thrombosis (\(\beta = 0.01, P = 7.57e^{-34}\)) and the risk for CAD (\(\beta = 0.06, P = 1.25e^{-08}\)).

**Obesity and UHRF1BP1**

Co-localization and subsequent MR analysis found UHRF1BP1 on chromosome 6 as a gene for which elevated expression (\(\beta = -0.013, P = 5.14e^{-16}\), Supplementary Data 3) contributes to the risk of obesity (defined here as lower whole body impedance). MR analysis revealed that elevated expression of UHRF1BP1 is positively associated (\(P < 5e^{-5}\)) with time spent watching TV but

---

**Fig. 1 Flowchart of our SNP-based multiomics data analysis approach to identify biomarkers that mediate the effect of risk factors on CAD.** Through this data analysis pipeline, we aimed to find biomarkers causally associated with the risk of CAD within known genomic regions for its risk factors. We started by collecting full GWAS summary statistics from studies that made their data publicly available. Next, we harmonized the data by converting them to SMR and GSMR formats. We then did the co-localization analysis to find SNPs that exert their effect through a molecular biomarker (probe). Next, we subjected the tagged probes to MR analysis to find biomarkers that are causally associated with a risk factor. Furthermore, we investigated whether the identified biomarkers are causally associated with the risk of CAD or other biomarkers for molecular insight.
negatively ($P < 5 \times 10^{-8}$) with phenotypes that lower the risk of CAD including birth weight, age at first child birth, education qualifications, and HDL levels (Supplementary Data 7). In this region, we note that GWAS data for CAD, eQTLs for UHRF1BP1 and eQTLs for ILRUN show correlated patterns (Fig. 3). Furthermore, MR analysis confirmed that change in the expression of these genes causally contributes to the risk of CAD (Fig. 3). UHRF1BP1 is binding protein 1 for UHRF1 which regulates chromatin structure and gene expression. ILRUN (inflammation and lipid regulator with UBA-like and NBR1-like domains) has immune functions. It is a negative regulator of innate antiviral response, and acts as an inhibitor of proinflammatory and antimicrobial cytokines. Further interrogation of our findings revealed the presence of two hotspot genomic regions whereby SNPs underlying several biomarkers and risk factors of CAD show overlapping association patterns.

**3p21.31 region**

Our analysis pipeline (co-localization and subsequent MR analysis) revealed several methylation and expression biomarkers for CNS and lifestyle risk factors for CAD within the 3p21.31 region (Supplementary Data 3). This suggests that genes in this region may be involved in the neural process consistent with other evidence for BSN, IP6K1, APEH, RBM5, and RBM6. MR analysis revealed that the identified biomarkers are causally contributing to numerous risk factors of CAD (Supplementary Data 7). The 3p21.31 region was the most populated locus in terms of the convergence of molecular biomarkers and risk factors for CAD. Among the 78 identified biomarkers, those with the highest number of associated-risk factors were in this region (Supplementary Data 7). For example, expression biomarkers for RBM6 and UBA7 were associated with 16 CAD risk factors at GWAS significance level (Supplementary Data 7 and Fig. 4).

---

**Fig. 2 Molecular path whereby S100A13 and F8 impact CAD.**

a) We found lower methylation at cg13375295 site, upstream of APOE, increases the level of S100A13 in the blood; this consequently contributes to higher level of LDL and higher risk of CAD. b) MR analysis also revealed higher methylation of ABO locus (see Supplementary Data 8 as well) is associated with higher level of F8 and this increases the risk of CAD by increasing the risk of thrombosis. Each point represents a SNP, the $x$-value of a SNP is its Beta effect size on a molecular probe and the horizontal error bar, represents the standard error around the Beta. The $y$-value of the SNP is its Beta effect size on a biomarker/trait and the vertical error bar represents the standard error around its Beta. The dashed line represents the line of best fit (a line with the intercept of 0 and the slope of $\beta$ from the MR test).
We noted that SNPs within BSN also display a trans-regulatory impact on the plasma protein level of stomatin (STOM). These data show that as this gene becomes methylated (as measured by cg05126514), the plasma protein level of STOM increases ($B = 0.33, P = 1.83 \times 10^{-84}$, Fig. 4). We find that higher plasma levels of stomatin are positively associated with CAD and several CAD risk factors and negatively with CAD protective factors (Supplementary Data 7). Of note, higher methylation at cg05126514 site was also associated with higher risk of CAD ($B = 0.06, P = 1.4 \times 10^{-8}$).

Stomatin encodes a member of a highly conserved family of integral membrane proteins. The encoded protein localizes to the cell membrane of red blood cells and other cell types, where it may regulate ion channels and transporters. Loss of localization of the encoded protein is associated with hereditary stomatocytosis, a form of hemolytic anemia. Although the wide distribution of stomatin and its constitutive expression suggest an important role for this protein in cell biology, perhaps as a house-keeping component, its function remains to be clarified. In this study, stomatin was mainly associated with CNS and lifestyle risk factors (Supplementary Data 7) suggesting a CNS function for this gene.

Among the other identified biomarkers in this region, change in expression of APEH was associated with CAD at GWAS significance. The gene has aminoacylase activity and is implicated in various biological processes. Concordantly, MR analysis revealed higher expression of APEH to be negatively associated with the risk for obesity, immature reticulocyte count and positively with CNS/lifestyle traits associated with higher cognition (Supplementary Data 7).

**HLA region**

Another congested region with regard to the convergence of risk factors for CAD and their biomarkers is the HLA region. Unlike the 3p21.31 locus, biomarkers identified in this region were associated to a more diverse group of risk factors (Supplementary Data 7). Following co-localization, and MR analysis, we identified 12 methylation biomarkers for white blood cell count, diabetes, obesity, height, and frequency of tiredness within the HLA region (Supplementary Data 7, Fig. 5).

cg19117063 and cg11530659 associated with white blood cell count and cg01521131 associated with the frequency of tiredness were associated with CAD at GWAS significance (Fig. 5). In this region, we note SNPs within CFB (complement factor B) gene display trans-regulatory effect on synaptic gene GRIA4. MR analysis indicates that the level of this protein in blood shows the correlation with biomarkers within the HLA region (Supplementary Data 9). Furthermore, we note that this biomarker is causally associated with 12 CAD risk factors at GWAS significance. A higher level of this protein was positively associated with a higher risk for CAD, TC levels, white blood cell counts and negatively with height and CNS/lifestyle traits associated with higher cognition (Supplementary Data 7). GRIA4 encodes glutamate receptor 4 which is a member of a family of glutamate receptors that mediate fast synaptic excitatory neurotransmission. Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. This finding also highlights the close
molecular crosstalk between the immune and central nervous systems with regard to CAD risk factors.

**DISCUSSION**

**CAD** is a global health problem mandating improved strategies for risk assessment and prevention. Here we devised a SNP-based multiomics data analysis approach to identify biomarkers that are causally associated with risk for CAD within genomic regions that are known to be associated with its risk factors.

We identified 12 methylation biomarkers associated with various risk factors of CAD within the HLA region. This is the most important area in the genome regarding infection and autoimmunity and is essential in adaptive and innate immunity. Previously, we reported that SNPs that contribute to the risk of CAD are highly enriched in genomic regions pertinent to immune function. We also noted STOM, a gene with hemo-immune function, to be under the trans-regulatory effect of SNPs within the BSN gene that has a neural function. Although biomarkers within 3p21.31 co-localize with CNS/lifestyle trait loci, genes in this region appear to have diverse functions, for example, APEH is involved in barbiturate dependence, kidney cortex necrosis, gene expression, and innate immune response. Microdeletions in this region are characterized by developmental delay, elevated serum creatine kinase levels, and white matter involvement. These findings may also explain why the biomarkers identified in this region were associated with multiple CAD risk factors (Supplementary Data 7).

Within the HLA region, SNPs in the complement factor B gene (CFB) have a trans-regulatory impact on GRIA4 protein level in blood and this in turn is associated with the risk of CAD and its attendant risk factors (Supplementary Data 7). GRIA4 is a neural gene involved in synaptic transmission. This finding gives further support to studies that reported HLA contributes to neuronal function and development. We noted that a number of seemingly non-CNS functional elements co-localize with CNS/lifestyle trait loci and mediate their impact on CAD. We found a methylation site within the HLA region that was a risk locus for the frequency of tiredness (Fig. 5 and Supplementary Data 3). A methylation site within Creatine Kinase, Muscle-Type...
(CKM) mediated the impact of lack of education qualifications (LEQ) on CAD. Higher methylation at this site was associated with a higher likelihood of LEQ, increased risk of CAD and lower expression of CKM (Fig. 6 and Supplementary Data 3). Altogether, these findings add support to the notion that CNS/lifestyle contributes to the risk of cardiovascular disease14,15.

Genomic regions that undergo epigenetic modification are considered as sites of gene-environment interactions. Previously we reported that SNPs that contribute to the risk of CAD are enriched in epigenetic sites associated with transcriptional activity2. Although in this study, the methylation datasets had the smallest sample size, majority 64% ($N = 50$) of the identified
biomarkers were methylation probes. Biomarkers identified in the HLA region were all methylation probes. We also noted the impact of methylation on several known cardiometabolic biomarkers. In addition to those presented in the previous sections, we found a methylation biomarker (cg21901847, Supplementary Data 3) within NOS3 that is associated with risk for early onset hypertension ($\beta = -0.42, P = 5.3e^{-9}$) and CAD ($\beta = 0.04, P = 7.5e^{-5}$). Similarly, a methylation site (cg18187658) within GALNT2, an established marker of TG and HDL-C, was associated with a higher blood level of TG ($\beta = 0.05, P = 1e^{-9}$) and the risk for CAD ($\beta = 0.03, P = 8.6e^{-6}$). A methylation site within ZNF664 was associated with higher HDL levels ($\beta = 0.03, P = 9.4e^{-11}$), lower risk for obesity ($\beta = -0.013, P = 3.5e^{-19}$) and CAD ($\beta = -0.02, P = 2.5e^{-8}$). Recent studies also demonstrate that epigenetics may play an important role in the development of CAD.17,18,19 Altogether, these findings indicate epigenetic reversal could have a profound impact in prevention and treatment of cardiovascular disease. In this regard, 3p21.31 and HLA region are prime candidates because they appear to be hotspots for interactions between risk factors of CAD and their biomarkers.

In this study, we connected different types of omics data (proteome, epigenome, transcriptome, phenotype) to obtain novel molecular and clinical insights. We achieved this by linking these data to a single backbone i.e. genome or SNPs. This is a logical approach because DNA provides the information for the development and maintenance of various layers of omics and the human organism is the outcome of these layers and their connections. This study provides a new paradigm whereby the ten-s-pedigree counts and lower risk of CAD. c) Similarly higher methylation at cg01521131 site was associated with low-frequency of tiredness and risk of CAD. Each point on the scatter plots represents a SNP, the x-value of a SNP is its Beta effect size on a molecular probe and the horizontal error bar, represents the standard error around the Beta. The y-value of the SNP is its Beta effect size on a molecular probe/CAD risk and the vertical error bar represents the standard error around its Beta. The dashed line represents the line of best fit (a line with the intercept of 0 and the slope of $\beta$ from the MR test).

Natural variations in the genome (SNPs) are historically used to study the genetics of omics and notably the phenotype. Summary association statistics from these studies are usually publicly available. Therefore, if we can relate these findings through SNPs, we can repurpose them. For example, by linking the expression of a gene to the phenotype and the epigenome, we can investigate the likely function of the gene and the location of regulatory elements that govern the expression of the gene. This allows us to understand the mechanism by which a gene impacts a phenotype. Our analysis pipeline (Fig. 1) was designed with the aim of combining omics data, in order to obtain such insights.

We started by asking the question, does the SNP-association signal for a factor and a functional element (Supplementary Data 1) co-localize in a genomic region. Supplementary Fig. 1 provides a graphical visualization for such a scenario. For this purpose, we systematically searched the genome and investigated the evidence of co-localization using the SMR (Summary-data-based Mendelian Randomization) test (version 1.03). The underlying assumption in this test is that, if in a region the effect of the top association signal (SNPA) on the risk factor is $\beta_r$ and its effect on a biomarker is $\beta_b$, we can estimate the effect of SNPA on the risk factor that is attributed to the biomarker ($\beta_{SMR}$) as:

$$\beta_{SMR} = \frac{\beta_r}{\beta_b} \quad (1)$$

Then, we can test whether the computed effect significantly deviates from the null (SNPA is not exerting its effect on risk factor through the biomarker) as:

$$T = \frac{\beta_{SMR} \text{ var(} \beta_{SMR} \text{)}}{\frac{\beta_r^2}{\text{Z}_x^2} + \frac{\beta_b^2}{\text{Z}_y^2} - \text{Z}_x^2} \quad (2)$$

where $T$-statistics of SNPs for the risk factor and the biomarker. The test is very useful because most published studies only provide access to summary level statistics and access to individual-level data is limited, due to privacy concerns and other logistical considerations.

From a biological perspective, a significant $\beta_{SMR}$ could also be due to linkage or to a situation where the top signal, for the risk factor and the biomarker, are close but not the same (Fig. 1). To exclude such instances, we used Heterogeneity In Dependent Instruments (HEDI) test as implemented in SMR software to exclude significant SMR effects that are due to linkage ($P_{\text{HEDI}} \leq 0.05$). The null model in the HEDI test is that there is a shared causal variant that affects both the risk factor and the biomarker (pleiotropy or causality scenario) while the alternative hypothesis indicates linkage. The HEDI test differentiates between these two scenarios by examining the change in pattern of $\beta_{SMR}$ for SNPs surrounding the SNPA, a non-homogeneous pattern indicates linkage.

Inherently, the SMR program cannot differentiate between pleiotropy (Biomarker $\rightarrow$ SNP $\rightarrow$ risk factor) or causality (SNP $\rightarrow$ Biomarker $\rightarrow$ risk factor) because to make a causal inference between the exposure and outcome, multiple SNPs (reference points) are required. Therefore, we next performed multi-SNPs summary-based Mendelian randomization analysis, also known as 2-sample Mendelian randomization (where exposure and outcome are measured in two separate samples). This method requires summary association statistics and it works by contrasting the effect sizes of SNPs on the exposure with the effect sizes of the SNPs on the outcome. In this context, a significant positive association indicates subjects that are genetically susceptible to have higher values of the exposure (e.g. a biomarker) tend to have higher values of the outcome. SNPs that are used in the MR test must pass a number of criteria. Notably a) they must not be in linkage disequilibrium, b) must not show pleiotropic effect, and c) must be significantly associated with the exposure. For this purpose, we obtained summary association statistics (Beta and Standard error) for non-

M. Nikpay and R. McPherson

Published in partnership with CEGMR, King Abdullahaz University npj Genomic Medicine (2021) 12
pleiotropic SNPs ($P_{HEDG} < 0.01$) that are independently ($r^2 < 0.05$) associated with a biomarker ($P < 5e^{-8}$) and used these as an instrument to investigate their impact on the risk factor. To facilitate the process of SNP selection and the MR test, we used the GSMR (Generalised Summary-data-based Mendelian Randomization) algorithm implemented in GCTA software (version 1.92) and passing the default setting criteria as specified above. As compared to other methods for 2-sample MR analysis, this algorithm automatically detects and removes SNPs that have a pleiotropic effect on both exposure and outcome; in addition, GSMR accounts for the sampling variance in $\beta$ estimates and the linkage disequilibrium (LD) among SNPs, such that it is statistically more powerful than other 2-sample MR approaches. Following this step (i.e. forward MR), we selected biomarkers causally contributing to risk factors ($P < 5e^{-8}$) and subjected them to the reverse-MR (Risk factor $\rightarrow$ Biomarker). Namely, we identified independent SNPs that are associated with the risk factor ($P < 5e^{-8}$) and contrasted their effect size on the risk factor with their effect size on the biomarker and excluded any risk factor-biomarker associations that showed significant evidence of reverse-causation ($P < 0.05$, Fig. 1). Biomarkers that also passed this step then were tested for their association with CAD by performing forward MR (Biomarker $\rightarrow$ CAD) and reverse MR (CAD $\rightarrow$ Biomarker). Biomarkers that passed this stage were then subjected to Bonferroni correction and those with forward MR (Bonferroni corrected $P < 0.05$) are reported in Supplementary Data 3.

**Data sources**

Our analysis pipeline requires full GWAS summary statistics. As such, we searched for GWAS studies of molecular features (i.e. QTL studies) that made their full results publicly available (Supplementary Data 1). Next, we harmonized the retrieved data by converting them to SMR or GSMR format for downstream analyses. We obtained GWAS summary statistics for SNPs that influence the human blood proteome (pQTLs) from Sun et al. GWAS summary statistics for SNPs that influence transcriptome (eQTLs) were from Võsa et al. and GWAS summary statistics for SNPs that influence DNA methylation (mQTLs) were derived from two studies. These studies are independent with reference to study participants and were conducted using blood samples. Although blood may not be the best tissue to study the biology of CAD, it appears to be an overall good proxy for many tissues. Liu et al. calculated pairwise genetic correlations ($r_g$) of local gene expression among 10 different tissues from GTEX, and found the mean $r_g$ between blood and other tissues is 0.71 (SD = 0.02). We also obtained GWAS summary statistics for CAD from the most recent meta-analysis of CARDioGRAMplusC4D and UK Biobank, and GWAS data for the major CAD risk factors (Supplementary Data 2) from a recent phenome-wide study. An important source of bias in genetic studies, including Mendelian randomization is population stratification. To address this issue, we collected GWAS summary statistics from studies...
carried out in European subjects and adjusted their results for the impact of population stratification. Our analysis pipeline also requires access to individual-level genotype data to estimate the linkage disequilibrium between SNPs. For this purpose, we used the genotype data from the INTERHEART study which is a sample of 854 subjects of European ancestry that we previously used in 1000 Genomes-based meta-analysis of CAD GWAS results. The current study was conducted in accordance with the principles outlined in the Declaration of Helsinki. Research Ethics Board of the Ottawa Hospital approved the research protocols and all participants provided written informed consent.

**Reporting summary**

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**DATA AVAILABILITY**

Data that support the findings of this study are available from: https://github.com/mnikpay/Multiomics-MR-scripts.git.

**CODE AVAILABILITY**

Instructions and scripts to carry out the analyses are available from: https://github.com/mnikpay/Multiomics-MR-scripts.git.

Received: 30 July 2020; Accepted: 6 January 2021; Published online: 11 February 2021

**REFERENCES**

1. Nikpay, M. et al. A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat. Genet.*, 47, 1121–1130 (2015).
2. Nikpay, M., Stewart, A. & McPherson, R. Partitioning the heritability of Coronary Artery Disease highlights the importance of immune-mediated processes and epigenetic sites associated with transcriptional activity. *Cardiovascular Res.*, 113, 973–983 (2017).
3. Nikpay, M. & Mohammadzadeh, S. Phenome-wide screening for traits causally associated with the risk of coronary artery disease. *J. Hum. Genet.*, 65, 371–380 (2020).
4. Nikpay, M. et al. Genome-wide identification of circulating-mRNA expression quantitative trait loci reveals the role of several miRNAs in the regulation of cardiometabolic phenotypes. *Cardiovascular Res.* https://doi.org/10.1093/cvr/cvz030 (2019).
5. Nikpay, M., Soubeyrand, S., Tahmasbi, R. & McPherson, R. Multiomics screening identifies molecular biomarkers causally associated with the risk of coronary artery disease. *Circulation: Genomic and Precision Medicine*, 0, https://doi.org/10.1161/CIRCGEN.119.002876 (2020).
6. Suhr, K. et al. Connecting genetic risk to disease end points through the human blood plasma proteome. *Nat. Commun.*, 8, 1–14 (2017).
7. Hu, F. et al. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. *Neuron*, 68, 654–667 (2010).
8. Okura, H. et al. HDL/apolipoprotein A1 binds to macrophage-derived progranulin and suppresses its conversion into proinflammatory granulins. *J. Atheroscler. Thromb.* 17, 568–577 (2010).
9. Sebastiani, P. et al. A serum protein signature of APOE genotypes in centenarians. *Aging Cell*, 18, e13023 (2019).
10. Emilsson, V. et al. Co-regulatory networks of human serum proteins link genetics to disease. *Science*, 361, 769–773 (2018).
11. Ambrose, R. L. et al. Molecular characterisation of ILRUN, a novel inhibitor of inflammatory and antimicrobial cytokines. *Hellyon*, 6, e00115 (2020).
12. Cebríán, C., Loike, J. D. & Sulzer, D. Neuronal MHC-I expression and its implications in synaptic function, axonal regeneration and Parkinson’s and other brain diseases. *Front. Neuroanat.*, 8, 114 (2014).
13. Eto, K. et al. Microdeletions of 3p21.31 characterized by developmental delay, distinctive features, elevated serum creatine kinase levels, and white matter involvement. *Am. J. Med. Genet. A* 161, 3049–3056 (2013).
14. Nikpay, M., Turner, A. W. & McPherson, R. Partitioning the pleiotropy between coronary artery disease and body mass index reveals the importance of low frequency variants and central nervous system–specific functional elements. *Circulation: Genom. Precis. Med.*, 11, e002050 (2018).
15. Nikpay, M. et al. Genetic mapping of habitual substance use, obesity-related traits, responses to mental and physical stress, and heart rate and blood pressure measurements reveals shared genes that are overrepresented in the neural synapse. *Hypertension Res.* 35, 585–591 (2012).
16. Khetarpal, S. A. et al. Loss of function of GALNT2 lowers high-density lipoproteins in humans, nonhuman primates, and rodents. *Cell Metab.*, 24, 234–245 (2016).
17. Rizzacasa, B., Amati, F., Romeo, F., Novelli, G. & Mehta, J. L. Epigenetic Modifica-
tion in Coronary Atherosclerosis. *J. Am. Coll. Cardiol.*, 74, 1352–1365 (2019).
18. Steenaard, R. V. et al. Tobacco smoking is associated with methylation of genes related to coronary artery disease. *Clin. epigenetics*, 7, 54 (2015).
19. McRae, A. F. et al. Identification of 55,000 replicated DNA methylation QTL. *Sci. Rep.*, 8, 17605 (2018).
20. Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat. Genet.*, 48, 481–487 (2016).
21. Zhu, Z. et al. Causal associations between risk factors and common diseases inferred from GWAS summary data. *Nat. Commun.*, 9, 224 (2018).
22. Sun, B. B. et al. Genomic atlas of the human plasma proteome. *Nature*, 558, 73–79 (2018).
23. Võsa, U. et al. Unraveling the polygenic architecture of complex traits using blood eQTL metaanalysis. *bioRxiv* 447367, https://doi.org/10.1101/447367 (2018).
24. Harmon, E. et al. Leveraging DNA-methylation quantitative-trait loci to characterize the relationship between methylic variation, gene expression, and complex traits. *Am. J. Hum. Genet.*, 103, 654–665 (2018).
25. Liu, X. et al. Functional architectures of local and distal regulation of gene expression in multiple human tissues. *Am. J. Hum. Genet.*, 100, 605–616 (2017).
26. van der Harst, P. & Verweij, N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. *Circulation Res.*, 122, 433–443 (2018).

**ACKNOWLEDGEMENTS**

This research was enabled in part by computational resources and support provided by the Compute Canada (https://www.computecanada.ca/). This study is supported by the Canadian Institutes of Health Research (FDN-154308 to RM).

**AUTHOR CONTRIBUTIONS**

M.N. did the analyses and drafted the manuscript. R.M. revised the manuscript and contributed to the interpretation of data.

**COMPETING INTERESTS**

The authors declare no competing interests.

**ADDITIONAL INFORMATION**

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41525-021-00174-z.

Correspondence and requests for materials should be addressed to M.N. or R.M.

Reprints and permission information reprints@nature.com

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.